AU2019369216B2 - Method of treatment of p53 WT tumors - Google Patents

Method of treatment of p53 WT tumors Download PDF

Info

Publication number
AU2019369216B2
AU2019369216B2 AU2019369216A AU2019369216A AU2019369216B2 AU 2019369216 B2 AU2019369216 B2 AU 2019369216B2 AU 2019369216 A AU2019369216 A AU 2019369216A AU 2019369216 A AU2019369216 A AU 2019369216A AU 2019369216 B2 AU2019369216 B2 AU 2019369216B2
Authority
AU
Australia
Prior art keywords
tumor
lenalidomide
hdm201
mdm4
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019369216A
Other languages
English (en)
Other versions
AU2019369216A1 (en
Inventor
Jingwei CHENG
James DECAPRIO
Donglim Esther Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2019369216A1 publication Critical patent/AU2019369216A1/en
Application granted granted Critical
Publication of AU2019369216B2 publication Critical patent/AU2019369216B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2019369216A 2018-10-30 2019-10-28 Method of treatment of p53 WT tumors Active AU2019369216B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752382P 2018-10-30 2018-10-30
US62/752,382 2018-10-30
PCT/US2019/058319 WO2020092221A1 (en) 2018-10-30 2019-10-28 Method of treatment of p53 wt tumors

Publications (2)

Publication Number Publication Date
AU2019369216A1 AU2019369216A1 (en) 2021-05-20
AU2019369216B2 true AU2019369216B2 (en) 2022-05-19

Family

ID=68582462

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019369216A Active AU2019369216B2 (en) 2018-10-30 2019-10-28 Method of treatment of p53 WT tumors

Country Status (10)

Country Link
US (1) US12115151B2 (https=)
EP (1) EP3873460B1 (https=)
JP (2) JP7653907B2 (https=)
KR (1) KR102879859B1 (https=)
CN (1) CN112996503A (https=)
AU (1) AU2019369216B2 (https=)
CA (1) CA3115716A1 (https=)
ES (1) ES2986421T3 (https=)
IL (1) IL282485B2 (https=)
WO (1) WO2020092221A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CN115216514B (zh) * 2022-08-01 2026-03-17 中国科学技术大学 Vam6（Vps39）作为靶点在药物筛选、基因编辑以及疾病治疗中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388093B (es) * 2016-11-15 2025-03-19 Novartis Ag Dosis y regimen para inhibidores de la interaccion hdm2-p53.

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Liao, G. et al., "The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, vol. 159, pages 1-9, DOI: 10.1016/J.EJMECH.2018.09.044 *
Lindner, S. et al., "The molecular mechanism of thalidomide analogs in hematologic malignancies", JOURNAL OF MOLECULAR MEDICINE, 2016, vol. 94, no. 12, pages 1327-1334, DOI: 10.1007/S00109-016-1450-Z *
Secchiero, P. et al., "Recent Advances in the Therapeutic Perspectives of Nutlin-3", CURRENT PHARMACEUTICAL DESIGN, 2011, vol. 17, no. 6, pages 569-577, DOI: 10.2174/138161211795222586 *
Stahl, M. et al., "Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications", CANCER, 2017, vol. 123, no. 10, pages 1703-1713, DOI: 10.1002/cncr.30585 *
Toledo, F. et al., "MDM2 and MDM4: p53 regulators as targets in anticancer therapy", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, 2007, vol. 39, no. 7-8, pages 1476-1482, DOI: 10.1016/J.BIOCEL.2007.03.022 *

Also Published As

Publication number Publication date
US12115151B2 (en) 2024-10-15
JP7653907B2 (ja) 2025-03-31
WO2020092221A1 (en) 2020-05-07
IL282485B1 (en) 2025-05-01
US20210379039A1 (en) 2021-12-09
EP3873460A1 (en) 2021-09-08
AU2019369216A1 (en) 2021-05-20
JP2022505884A (ja) 2022-01-14
JP2025026846A (ja) 2025-02-26
KR20210087958A (ko) 2021-07-13
IL282485B2 (en) 2025-09-01
ES2986421T3 (es) 2024-11-11
EP3873460B1 (en) 2024-06-12
KR102879859B1 (ko) 2025-11-04
CN112996503A (zh) 2021-06-18
CA3115716A1 (en) 2020-05-07
IL282485A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
Forte et al. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide
Zhao et al. Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages
JP2025026846A (ja) ｐ５３ＷＴ腫瘍の処置の方法
US20130288980A1 (en) Targeting senescent and cancer cells for selective killing by interference with foxo4
El Atat et al. Molecular targeted therapy: A new avenue in glioblastoma treatment
US20130288981A1 (en) Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
WO2019246430A1 (en) Methods of treating disorders
WO2015073319A1 (en) Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction
Hu et al. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer
Xu et al. Overexpression of nucleotide metabolic enzyme DUT in hepatocellular carcinoma potentiates a therapeutic opportunity through targeting its dUTPase activity
Shah et al. Sustained aurora kinase B expression confers resistance to PI3K inhibition in head and neck squamous cell carcinoma
Zhu et al. EZH2 inhibition and 5-azacytidine enhance antitumor immunity in PTEN-deficient glioblastoma by activation viral mimicry response
Wang et al. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes
HK40048199B (en) Method of treatment of p53 wt tumors
HK40048199A (en) Method of treatment of p53 wt tumors
Yang et al. Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axis
Brunet et al. Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
US20240124610A1 (en) Methods for treating her2-negative or her2-low cancer
US20240285587A1 (en) Novel therapeutic agent that suppresses metastasis and proliferation of osteosarcoma and glioma
RU2830814C2 (ru) Способ лечения рака поджелудочной железы
Abou-Hamad The Roles of SOX9 and SOX10 in Therapy Resistance in BRAFV600E-Induced Melanoma
Prince et al. Women in molecular and cellular oncology, volume II: 2022
Chembo Disrupting NRF2-Driven Cancer Biology Through One-Carbon Metabolism Inhibition
Manara Deciphering the Impact of Translation Inhibition in Blood Malignancies
Benítez García Identification and Preclinical Evaluation of Asenapine Maleate as a Direct Survivin Inhibitor for Lung Cancer Therapy and Sensitization to Proapoptotic Treatments

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)